Ana Pinho,1,2 Susana Sampaio,2 Manuel Pestana2,31Department of Nephrology, Faro Hospital, Faro, Portugal; 2Department of Nephrology, Hospital São João, Porto, Portugal; 3Medical School and Nephrology Research and Development Unit, University of Porto, Porto, PortugalAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality and death-censored graft loss after renal transplantation.1 Acute cardiovascular events have been reported as the principal clinical manifestations, but hypertension could be a form of ASCVD presentation, being able to promote its progression undetected.2